Smith Chas P & Associates PA Cpas Decreases Stock Holdings in Merck & Co., Inc. $MRK

Smith Chas P & Associates PA Cpas reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 35.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 228,527 shares of the company’s stock after selling 126,721 shares during the period. Merck & Co., Inc. accounts for about 1.7% of Smith Chas P & Associates PA Cpas’ portfolio, making the stock its 29th largest holding. Smith Chas P & Associates PA Cpas’ holdings in Merck & Co., Inc. were worth $19,180,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in MRK. Charles Schwab Investment Management Inc. boosted its stake in Merck & Co., Inc. by 9.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock worth $4,263,991,000 after buying an additional 4,636,183 shares during the last quarter. DLD Asset Management LP acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth $2,889,340,000. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $2,858,570,000. Franklin Resources Inc. boosted its position in shares of Merck & Co., Inc. by 23.5% during the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after acquiring an additional 5,135,748 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Fisher Asset Management LLC now owns 25,013,697 shares of the company’s stock valued at $1,980,084,000 after acquiring an additional 567,900 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: KEYTRUDA combo late‑stage wins and regulatory milestones broaden Merck’s oncology franchise and support revenue durability; management has reorganized the human health business and added oncology leadership to commercialize combinations. Merck’s KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK)
• Positive Sentiment: Analyst pieces point to Keytruda as the main growth driver (roughly half of pharma sales), explaining recent revenue strength and underpinning 2026 earnings expectations. Continued label expansions and approvals are key upside drivers. Merck’s Keytruda Drives its 2025 Revenue Surge: What’s Ahead?
• Positive Sentiment: Merck signed a multi‑year collaboration with AI firm Tempus to accelerate AI‑driven precision medicine, which could speed biomarker identification and trial efficiency for oncology assets. AI-Powered Tempus Inks New Multi-Year Merck Deal
• Positive Sentiment: Value-focused coverage argues MRK remains reasonably valued after a strong run, supported by diversification (e.g., Enflonsia for RSV) and a plan to insulate revenue before Keytruda’s 2028 patent expiry. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works
• Neutral Sentiment: Management presentation at the TD Cowen health‑care conference (transcript) reiterates strategy and pipeline priorities — useful for modeling but not an immediate catalyst. Merck Presents at TD Cowen Conference (Transcript)
• Neutral Sentiment: Coverage noting strong KEYTRUDA combo data also raises patent and competitive questions as exclusivity approaches, a mixed-read that investors are parsing for timing and replacement revenue. Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions
• Negative Sentiment: Merck shares have recently pulled back in some sessions after the rally, reflecting profit‑taking and investor focus on near‑term uncertainties (patent cliffs, readout timing). Merck (MRK) Stock Dips While Market Gains: Key Facts

Merck & Co., Inc. Price Performance

Shares of MRK opened at $119.67 on Wednesday. The firm has a 50-day simple moving average of $113.56 and a two-hundred day simple moving average of $98.01. The stock has a market cap of $295.87 billion, a PE ratio of 16.44, a P/E/G ratio of 2.33 and a beta of 0.27. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter last year, the company posted $1.72 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Barclays assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. Bank of America raised their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Scotiabank lifted their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research report on Thursday, December 4th. The Goldman Sachs Group upped their price objective on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Finally, Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $125.88.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.